Adas, M. A., Alveyn, E., Cook, E., Dey, M., Galloway, J. B., & Bechman, K. (2022). The infection risks of JAK inhibition. Expert Review of Clinical Immunology, 18(3), 253–261. https://doi.org/10.1080/1744666X.2022.2014323
Abidi, M. Z., Coelho-Prabhu, N., Hargreaves, J., Weiland, T., Van Dyken, I., Tande, A., Tosh, P. K., Walker, R. C., & Cummins, N. W. (2014). Mucormycosis in patients with inflammatory bowel disease: Case series and review of the literature. Case Reports in Medicine, 2014, Article 637492. https://doi.org/10.1155/2014/637492
American Cancer Society. (2022, September 19). Non-Hodgkin lymphoma risk factors. https://www.cancer.org/cancer/non-hodgkin-lymphoma/causes-risks-prevention/risk-factors.html
American College of Rheumatology. (2022, February). Tumor necrosis factor (TNF) inhibitors. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/TNF-Inhibitors
Andersen, N. N., & Jess, T. (2014). Risk of infections associated with biological treatment in inflammatory bowel disease. World Journal of Gastroenterology, 20(43), 16014–16019. https://doi.org/10.3748/wjg.v20.i43.16014
Andersen, N. N., Pasternak, B., Basit, S., Andersson, M., Svanström, H., Caspersen, S., Munkholm, P., Hviid, A., & Jess, T. (2014). Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA, 311(23), 2406–2413. https://doi.org/10.1001/jama.2014.5613
Baoqi, Y., Dan, M., Xingxing, Z., Xueqing, Z., Yajing, W., Ke, X., & Liyun, Z. (2022). Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis. Frontiers in Cardiovascular Medicine, 8, Article 812631. https://doi.org/10.3389/fcvm.2021.812631
Benjamin, O., Goyal, A., & Lappin, S. L. (2022, July 4). Disease modifying anti-rheumatic drugs (DMARD). StatPearls [Internet]. Retrieved January 3, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK507863/
Cohen, S., & Amy Cannella. (2022, July 27). Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis. UpToDate. Retrieved January 3, 2023, from https://www.uptodate.com/contents/disease-modifying-antirheumatic-drugs-dmards-in-rheumatoid-arthritis-beyond-the-basics
Dinarello, C. A. (2000). Proinflammatory cytokines. Chest, 118(2), 503–508. https://doi.org/10.1378/chest.118.2.503
Dommasch, E., & Gelfand, J. M. (2009). Is there truly a risk of lymphoma from biologic therapies?. Dermatologic Therapy, 22(5), 418–430. https://doi.org/10.1111/j.1529-8019.2009.01258.x
Drugs.com. (n.d.). Drug interactions between Arava and Humira. https://www.drugs.com/drug-interactions/arava-with-humira-1440-852-102-32.html
Drugs.com. (2022, March 25). Humira. https://www.drugs.com/humira.html
Ellis, C. R., & Azmat, C. E. (2022, December 3). Adalimumab. StatPearls [Internet]. Retrieved January 3, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK557889/
Esmail, H., & Wilkinson, R. J. (2017). Minimizing tuberculosis risk in patients receiving anti-TNF therapy. Annals of the American Thoracic Society, 14(5), 621–623. https://doi.org/10.1513/annalsats.201701-055ed
Filler, S. G., Yeaman, M. R., & Sheppard, D. C. (2005). Tumor necrosis factor inhibition and invasive fungal infections, Clinical Infectious Diseases, 41(Suppl 3), S208–S212, https://doi.org/10.1086/430000
Gerriets, V., Goyal, A., & Khaddour, K. (2022, July 4). Tumor necrosis factor inhibitors. StatPearls [Internet]. Retrieved January 3, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK482425/
Hedayat, M., Mahmoudi, M. J., Rose, N. R., & Rezaei, N. (2010). Proinflammatory cytokines in heart failure: Double-edged swords. Heart Failure Reviews, 15(6), 543–562. https://doi.org/10.1007/s10741-010-9168-4
Humira.com. (n.d.). Before making a decision, get the facts. Retrieved January 3, 2023, from https://www.humira.com/global/safety-side-effects
Hussain, A., Tarahomi, T., Singh, L., Bollampally, M., Heydari-Kamjani, M., & Kesselman, M. M. (2021). Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis. Cureus, 13(9), Article e17938. https://doi.org/10.7759/cureus.17938
IBD Clinic. (n.d.). Side effects. http://www.ibdclinic.ca/treatment/medications/biological-therapy/adalimumab-humira/side-effects/
Kotton, C. N., & Winthrop, K. L. (n.d.). Immunizations in autoimmune inflammatory rheumatic disease in adults. UpToDate. Retrieved January 3, 2023, from https://www.uptodate.com/contents/immunizations-in-autoimmune-inflammatory-rheumatic-disease-in-adults/print#H1201675568
Lopes, J., Machado, A., Martins, S., Pires, S., Branco, C., Fragoso, J., Guerra, D., Campos, P., Brandao, M., Carvalheiras, G., & Mendonca, T. (2017). The challenge of tuberculosis infection related to adalimumab: A subtle and rare presentation. Journal of Medical Cases, 9(1), 23–25. https://doi.org/10.14740/jmc2979w
Mayo Clinic. (2022, September 14). Urinary tract infection (UTI). https://www.mayoclinic.org/diseases-conditions/urinary-tract-infection/symptoms-causes/syc-20353447
Mayo Clinic. (2023, January 1). Adalimumab (subcutaneous route). https://www.mayoclinic.org/drugs-supplements/adalimumab-subcutaneous-route/side-effects/drg-20066817?p=1
Mori, S., & Fujiyama, S. (2015). Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World Journal of Gastroenterology, 21(36), 10274–10289. https://doi.org/10.3748/wjg.v21.i36.10274
Natividade, N. B., Felix, P. A. O., & Lerer, C. (2017). Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis. Anais Brasileiros de Dermatologia, 92(5 Suppl 1), 85–87. https://doi.org/10.1590/abd1806-4841.20175871
Parakkal, D., Sifuentes, H., Semer, R., & Ehrenpreis, E. D. (2011). Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: Expanding the groups at risk. European Journal of Gastroenterology & Hepatology, 23(12), 1150–1156. https://doi.org/10.1097/MEG.0b013e32834bb90a
Schumacher, S. M., & Prasad, S. V. N. (2018). Tumor necrosis factor-α in heart failure: An updated review. Current Cardiology Reports, 20(11), 117. https://doi.org/10.1007/s11886-018-1067-7
Solhjoo, M., Goyal, A., & Chauhan, K. (2022, April 6). Drug-induced lupus erythematosus. StatPearls [Internet]. Retrieved January 3, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK441889/
Thai, A., & Prindiville, T. (2010). Hepatosplenic T-cell lymphoma and inflammatory bowel disease. Journal of Crohn's and Colitis, 4(5), 511–522. https://doi.org/10.1016/j.crohns.2010.05.006
Toufaily, A. (2020). Severe cardiomyopathy induced by adalimumab administration for Crohn's disease. Journal of Cardiology Case Reports, 3(1). https://doi.org/10.15761/jccr.1000129
Williams, E. L., Gadola, S., & Edwards, C. J. (2009). Anti-TNF-induced lupus. Rheumatology, 48(7), 716–720, https://doi.org/10.1093/rheumatology/kep080